Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More
Caris Life Sciences Inc CAI
$15.67
▼ -2.61%
($-0.42)
📅 Earnings This Week
Open
$16.05
Prev Close
$16.09
Day Range
$15.23 – $16.14
52W Range
$14.19 – $42.50
Market Cap
$4.43B
P/E (TTM)
130.35
Beta
0.31
EPS (TTM)
$0.11
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2025-06-18 |
| Shares Out. | 282,680,000 |
| Website | carislifesciences.com/ ↗ |
| Phone | 18667718946 |
| Employees | 1,846 |
| Revenue | $216.2M |
| Gross Profit | $141.3M |
| Net Income | -$510,000 |
| Free Cash Flow | $83.5M |
| Total Assets | $1.16B |
| Total Liabilities | $568.9M |
| Equity | $593.5M |
About Caris Life Sciences Inc
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Caris Life Sciences Inc is a publicly traded company under the ticker symbol CAI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)